Greater Paris Metropolitan Region
With more than 20 years of professional experience, I have worked both in Diagnostics and Drug Development Industries in various areas (Hepatology, Gastroenterology, Genetics, Neuro-Muscular Diseases, Immuno-Oncology, Allergies and Auto-Immune Diseases). I have developed a successful track record in identifying and negotiating opportunities of collaborations and licensing, in effectively managing several strategic alliances and partnerships. I’ve coordinated projects with diverse and transversal teams with internal and external stakeholders in a multicultural and international environment.
ALLIANCE MANAGEMENT: • Management of strategic collaborations and license agreements with Pharma companies (Sanofi, Roche), Biotechs (Molecular Partners) and Academics/Hospitals in the field of Nuclear Medicine (Theranostics) for treating cancers (GEP-NET, SCLC, various solid cancers) o Preparation, Coordination and Animation of governance meetings o Joint Management with Project Leaders and transversal subteams (preclinical, regulatory, CMC, clinical, IP, Communication) BUSINESS DEVELOPMENT: • Identify new opportunities and negotiation of diverse agreements • Participations to conferences of interest: ASCO, SNNMI, EANM, BIO
ALLIANCE MANAGEMENT: • Management of strategic collaborations or license agreements with Pharma companies, Academics, Hospitals, CRO, Biotechs and Patients Associations o Overseeing execution and compliance with agreements o Preparation, Coordination and Animation of Joint Steering Committees, Joint Program Team meetings o Transversal Management of subteams (preclinical, regulatory, CMC, clinical, Intellectual Property, translational studies, biomarkers and commercial) o Lead of Asset Strategy Working Group o Reports and Presentations BUSINESS DEVELOPMENT: • Opportunity identification, due diligence, negotiation to final transaction in complex contracts in coordination with R&D, financial, legal and IP functions to maximize portfolio and company value • Commercial assessment: TPP, forecasts, competition and market access, analysis of business cases, for internal and external projects in several diseases areas (GI: CD, UC, Celiac,/ I-O: Glioblastoma, Renal Cell Carcinoma, indolent Non-Hodgkin Lymphoma, Colorectal Cancer/A-I: Lupus (SLE, NL), Rhumatoid Arthritis, Type 1 Diabetes, Multiple Sclerosis) • Participation to the COMEX and Board reports • Applications to non-dilutive fundraising • Support to R&D by scouting and leading the negotiation of simple contracts: CDA, MTA, Collaboration and Services agreements • Participations and oral presentations at scientific, medical and business conferences
ALLIANCE MANAGEMENT : • Management of collaborations or MSA with Pharma companies, Academics labs, Hospitals, Industrials, Biotechs, Associations • Proactive and effective communication and governance • Organisation of meetings • Management of translational studies BUSINESS DEVELOPMENT : • Assessment of new opportunities, structuring and negotiation of industrial partnerships • Robust market and competitive analyses across different therapeutic areas of strategic interest (Hepatology: NASH, Cirrhosis and its complications SBP and HE/ GI: CD and UC/ I-O: Glioblastoma) • Support for the preparation of Dataroom for Due Diligence • Identification of Key Opinions Leaders and Organization of Scientific and Clinical Advisory Boards INTELLECTUAL PROPERTY : • Management of Enterome Portfolio with Patent Attorneys PROJECT MANAGEMENT: • Management of translational studies in Inflammatory Bowel Diseases (Crohn’s and Ulcerative Colitis), Necrotizing Enterocolitis, Cirrhosis, Celiac Disease COMMUNICATION: • Website • Press releases • Posters/publications SCIENTIFIC AND COMPETITIVE INTELLIGENCE/REPORTING • Attendance to conferences: Hepatology (AASLD, EASL, AFEF, Paris Hepatology Conference, JFHOD), Gastroenterology (DDW, UEGW, ECCO, GETAID), Oncology (ESMO, AACR), Business (BIO, BIOEUROPE), Microbiome (IHMC, Microbiome R&D and Business Collaboration Forum, European Microbiome Congress, Microbiome Drug Development Summit), Nutrition (ICTRHN)
TECH TRANSFER : • Implementation of 3 diagnostic platforms in genetics laboratories from the logistics to the training and support MARKETING: • Market studies in Genetics, Neuromuscular Diseases (FSHD, DMD, MD), Oncology (BRCA, HNPCC, HPV related) • Pricing/Revenue Evaluation/ Risk Analysis • Market Opening with French National Hospital/Market Renewal COMMERCIAL: • New clients prospection in academic and diagnostics labs • Sales of Molecular Combing Technology: devices and consumables • Follow up of client activities and publications • Participation as exhibitor in medical and scientific meetings
COMMERCIAL: • New clients prospecting in academic and diagnostics hospital labs • Sales of Molecular Combing Technology: devices and consumables MARKETING: • Market studies in Genetics • Technical and scientific competitive intelligence/Reporting • Pricing/Revenue Evaluation/ Risk Analysis REGULATORY: • Writing of procedures for the Quality and CE marking COMMUNICATION: • Website/ Animation • Brochures/Goodies • Preparation and participation as exhibitors in medical and scientific meetings: Genetics and Cytogenetics (ESHG, ASHG/ICHG, ACLF, ACMG, ECA, Assises de Génétique), Myology (ICNMD, SFM), Biotechnology (Biotechnica, Convention Medicen Paris Région), Oncology (IMPAKT Breast Cancer Conference)
RESEARCH: • Coordination of a whole genome study for genes involved in liver fibrosis mechanisms in HCV patients (ANRS project : Cochin, Necker and Pitié-Salpêtrière Hospitals) : Inclusion of patients, questionnaire and informed consent signatures, databases, DNA identification and analyses on genomic platform Illumina (Pitié Hospital) • Screening of liver fibrosis and steatosis in Hispanic obese populations (Loma Linda University Medical Center, California, USA), in subjects consulting the CPAM (Caisse Primaire d’Assurance Maladie) of Paris (evaluation in general population) : samples collection, organization and performance of the biomarkers analyses, databases, calculation, results delivery MARKETING : • Targeting of potential hospitals and labs/ Evaluation of potential test numbers per center • Newsletter writing, website updating • Writing of brochures for patients and physicians • Scientific and competitive intelligence COMMERCIAL : • Meetings with Heads of Department in Hepatology and Biochemistry/Medical Biology in French hospitals to promote the use of non invasive diagnostics tests commercialized by BioPredictive and to facilitate their adoption in clinical practices. • Participation as exhibitor in National and International Conferences in Hepatology and Infectiology (EASL, AASLD, JFHOD, AFEF...)
RESEARCH : • Basic Research : Proteomics Studies in patients with HCV hepatitis by SELDI-TOF/MALDI-TOF Spectrometries and Chromatographies • Applied Research: National and International studies in Hepatology on screening of liver fibrosis, steatosis and cirrhosis by FibroTest/ FibroMAX > FIBROFRANCE Studies : in collaboration with the AP-HP (Assistance Publique Hôpitaux de Paris), the departments of Hepatology and Gastroenterology, Diabetology, Endocrinology, Biochemistry, Pathology, Digestive Surgery of la Pitié-Salpêtrière Hospital, EFS (French Bloodstock Agency), CPAM of Paris > Other studies on children and adults with hepatitis related to HCV, HBV infection, co-infection with HIV and Paludism, auto-immune hepatitis: in collaboration with several AP-HP hospitals and with hospitals from Egypt, Gabon, Ireland, Italy, Japan, USA, Vietnam > Transferability studies of biochemical assays for pharmaceutical companies specialized in in vitro Diagnostics (Dade Behring, Bayer, Beckman, Orthodiagnostics, Diagam, Abbott, Roche) and private medical test laboratories > Evaluation of an alcoholism biomarker : carbohydrate deficiency transferrin (CDT) for Dade Behring (Siemens) > Pre-analytical and analytical validations for assays of FibroTest parameters: comparison between serum and plasma, storage temperature over time, lipemia and hemolysis impact > Protocols of comparison between evaluation techniques of liver fibrosis: elastometry (FibroScan) or other biological markers • Clinical Research : > National multicentric study AXCAN-URSONASH: treatment and follow up of liver fibrosis, steatosis and steato-hepatitis in NASH patients COMMUNICATION: • Posters and publications • Meetings with pharmas, clinicians, biologists and patients TRAINING AND MANAGEMENT: • Training and Management of internal and external students in Pharmacy on ‘Fibrosis Biomarkers Department’